# A Phase I Study of CX5461

> **NCT02719977** · PHASE1 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 41 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** CX5461

## Key facts

- **NCT ID:** NCT02719977
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-13
- **Primary completion:** 2020-01-30
- **Final completion:** 2023-01-18
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719977, "A Phase I Study of CX5461". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02719977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*